CAPTRUST Financial Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,450	Closed	-$120K	–	2870
2022 Q2	$120K	Hold	2,450	–	–	﹤0.01%	2072
2022 Q1	$147K	Hold	2,450	–	–	﹤0.01%	1954
2021 Q4	$195K	Sell	2,450 -1,031	-30%	-$86.6K	﹤0.01%	1661
2021 Q3	$308K	Hold	3,481	–	–	﹤0.01%	1284
2021 Q2	$347K	Buy	3,481 +2,250	+183%	+$200K	﹤0.01%	1178
2021 Q1	$111K	Buy	+1,231	New	+$122K	﹤0.01%	1882

Other funds holding GNOM

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

CAPTRUST Financial Advisors's GNOM Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q3 2022, closing a stake of 2,450 shares — an estimated $120K sold.

CAPTRUST Financial Advisors first reported a position in GNOM in Q1 2021 and held it in 6 quarters. The position peaked at $347K in Q2 2021. 58 funds tracked by Wall St. Rank hold GNOM as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Global X Genomics & Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 2,450 Global X Genomics & Biotechnology ETF shares in Q3 2022, an estimated $120K.
CAPTRUST Financial Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q1 2021 and held it in 6 quarters.
CAPTRUST Financial Advisors's Global X Genomics & Biotechnology ETF position peaked at $347K in Q2 2021.
58 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.